Stockreport

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

ReShape Lifesciences, Inc.  (RSLS) 
US:NASDAQ Investor Relations: ir.enteromedics.com
PDF Significant Reduction in Overall Operating Expenses of 40.6% in the First Nine Months of 2024 Compared to the First Nine Months of 2023 Entered into Merger Agreement [Read more]